SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X, Sekino Y, Li HT, Fu G, Yang Z, Zhao S, Gujar H, Zu X, Weisenberger DJ, Gill IS, Tulpule V, D'souza A, Quinn DI, Han B, Liang G.
Zhou X, et al. Among authors: weisenberger dj.
Cancer Res. 2023 Nov 15;83(22):3813-3826. doi: 10.1158/0008-5472.CAN-23-0401.
Cancer Res. 2023.
PMID: 37695044
Free PMC article.